Insider Shelly Pinto Files Form 4 for ALX Oncology Holdings

TL;DR

**Insider Shelly Pinto just filed a Form 4 for ALX Oncology, signaling a change in her holdings.**

AI Summary

Shelly Pinto, a reporting insider, filed a Form 4 on March 23, 2026, indicating changes in her beneficial ownership of ALX Oncology Holdings Inc. securities. This filing, with an accession number of 0001193125-26-119703, covers the period ending March 19, 2026. While the filing details aren't fully provided, it signals an insider transaction, which can be important for investors as it reflects an insider's view on the company's prospects. Investors should monitor the specific transaction details to understand if Pinto bought or sold shares, as this could influence their perception of ALX Oncology's future performance.

Why It Matters

Insider transactions can signal confidence or concern from those with the most intimate knowledge of a company, potentially influencing investor sentiment and stock price.

Risk Assessment

Risk Level: medium — The risk is medium because while an insider filing is important, the specific details of the transaction (buy/sell, quantity) are not provided in this summary, making the immediate impact unclear.

Analyst Insight

A smart investor would access the full '4 ownership.html' document to determine if Shelly Pinto bought or sold shares and the quantity, as this specific information is crucial for interpreting the insider's sentiment towards ALX Oncology Holdings Inc.

Key Numbers

• 2026-03-23 — Filing Date (Date the Form 4 was filed with the SEC)
• 2026-03-19 — Period of Report (Date of the transaction being reported)
• 0001193125-26-119703 — SEC Accession No. (Unique identifier for this specific filing)

Key Players & Entities

• Pinto Shelly (person) — Reporting insider
• ALX ONCOLOGY HOLDINGS INC (company) — Issuer of securities
• 0001857740 (person) — CIK of Shelly Pinto
• 0001810182 (company) — CIK of ALX Oncology Holdings Inc.
• 001-39386 (dollar_amount) — File number for ALX Oncology Holdings Inc.

Forward-Looking Statements

• The specific details of Shelly Pinto's transaction (buy or sell, quantity) will be revealed upon full review of the 4 ownership.html document. (Shelly Pinto) — high confidence, target: 2026-03-23
• If the transaction is a significant purchase, investor sentiment for ALX Oncology Holdings Inc. may become more bullish. (ALX ONCOLOGY HOLDINGS INC) — medium confidence, target: short-term

FAQ

Filing Documents

• ownership.html (4)
• ownership.xml (4) — 3KB
• 0001193125-26-119703.txt ( ) — 5KB

From the Filing

SEC FORM 4 SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. 1. Name and Address of Reporting Person * Pinto Shelly (Last) (First) (Middle) C/O ALX ONCOLOGY HOLDINGS INC. 323 ALLERTON AVENUE (Street) SOUTH SAN FRANCISCO CALIFORNIA 94080 (City) (State) (Zip) UNITED STATES (Country) 2. Issuer Name and Ticker or Trading Symbol ALX ONCOLOGY HOLDINGS INC [ ALXO ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title below) Other (specify below) SVP, FINANCE AND CAO 2a. Foreign Trading Symbol 3. Date of Earliest Transaction (Month/Day/Year) 03/19/2026 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person 4. If Amendment, Date of Original Filed (Month/Day/Year) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 03/19/2026 S (1) 903 D $ 2.17 86,805 D Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Explanation of Responses: 1. The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of perfomance-based restricted stock units. /s/ Shelly Pinto 03/23/2026 ** Signature of Reporting Person Date Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. * If the form is filed by more than one reporting person, see Instruction 4 (b)(v). ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. * Form 4: SEC 1474 (03-26)

View Full Filing

View this 4 filing on SEC EDGAR